Mistletoe-Based Drugs Work in Synergy with Radio-Chemotherapy in the Treatment of Glioma In Vitro and In Vivo in Glioblastoma Bearing Mice

Figure 4

Additive and synergistic effects. LNT-229 (upper panel), LN-308 (middle panel), and SMA-560 (lower panel) glioma cells either were exposed to radio-chemotherapy alone (white bar), with viscumin (grey bar), or were exposed to radio-chemotherapy in combination with ISCADOR Qu (ISC Qu), Aviscumine (Avi), or native ML-1 (black bars). The dashed bars indicate the predicted effect of combined treatment according to the fractional product method (for details, see Section 2). The following conditions were chosen: LNT-229: 3 Gy, 3 µM TMZ, 3.6 ng/ml ISCADOR Qu, or Aviscumine, 4.8 ng/ml native ML-1; LN-308: 1.5 Gy, 10 µM TMZ, 16 ng/ml ISCADOR Qu, Aviscumine, or native ML-1; SMA-560: 3 Gy, 30 µM TMZ, 6.5 ng/ml ISCADOR Qu, 1.5 ng/ml Aviscumine, or 2 ng/ml native ML-1 (n=3; ±SD).